JP2013511554A5 - - Google Patents

Download PDF

Info

Publication number
JP2013511554A5
JP2013511554A5 JP2012540142A JP2012540142A JP2013511554A5 JP 2013511554 A5 JP2013511554 A5 JP 2013511554A5 JP 2012540142 A JP2012540142 A JP 2012540142A JP 2012540142 A JP2012540142 A JP 2012540142A JP 2013511554 A5 JP2013511554 A5 JP 2013511554A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
linear peptide
linear
xaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012540142A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013511554A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/057700 external-priority patent/WO2011063367A1/en
Publication of JP2013511554A publication Critical patent/JP2013511554A/ja
Publication of JP2013511554A5 publication Critical patent/JP2013511554A5/ja
Withdrawn legal-status Critical Current

Links

JP2012540142A 2009-11-23 2010-11-23 メラノコルチン−１受容体特異的線状ペプチド Withdrawn JP2013511554A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26348609P 2009-11-23 2009-11-23
US61/263,486 2009-11-23
PCT/US2010/057700 WO2011063367A1 (en) 2009-11-23 2010-11-23 Melanocortin-1 receptor-specific linear peptides

Publications (2)

Publication Number Publication Date
JP2013511554A JP2013511554A (ja) 2013-04-04
JP2013511554A5 true JP2013511554A5 (enExample) 2014-01-23

Family

ID=44060072

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012540142A Withdrawn JP2013511554A (ja) 2009-11-23 2010-11-23 メラノコルチン−１受容体特異的線状ペプチド

Country Status (13)

Country Link
US (3) US8933194B2 (enExample)
EP (1) EP2504351A4 (enExample)
JP (1) JP2013511554A (enExample)
KR (1) KR20120102716A (enExample)
CN (1) CN102712674A (enExample)
AU (1) AU2010321739A1 (enExample)
BR (1) BR112012011780A2 (enExample)
CA (1) CA2781405A1 (enExample)
EA (1) EA201290295A1 (enExample)
IL (1) IL219946A0 (enExample)
MX (1) MX2012005859A (enExample)
WO (1) WO2011063367A1 (enExample)
ZA (1) ZA201203331B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA021897B1 (ru) * 2009-11-23 2015-09-30 Палатин Текнолоджиз, Инк. Циклические пептиды, специфичные к рецептору меланокортина-1
IT1404931B1 (it) * 2010-06-11 2013-12-09 Medivis S R L Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
WO2012158960A2 (en) * 2011-05-17 2012-11-22 H. Lee Moffitt Cancer Center & Research Institute, Inc. Melanocortin 1 receptor ligands and methods of use
US9290539B2 (en) 2011-05-17 2016-03-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanotropin ligands for skin care
WO2013067309A1 (en) * 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
US9534018B2 (en) 2012-03-13 2017-01-03 Tensive Controls Inc. Melanocortin analogs having enhanced activity and transport
US20170022252A1 (en) 2014-06-10 2017-01-26 The Arizona Board Of Regents On Behalf Of The University Of Arizona Novel modulators of melanocortin receptors
US9821023B2 (en) 2014-06-10 2017-11-21 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of central nervous system (CNS) disorders and mood disorders
US9814755B2 (en) 2014-06-10 2017-11-14 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of depression and anxiety
CN104436159A (zh) * 2014-12-09 2015-03-25 天津医科大学眼科医院 一种新型滴眼液对治疗干眼的用途
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
WO2017019664A1 (en) 2015-07-28 2017-02-02 University Of Iowa Research Foundation Compositions and methods of treating cancer
US10550157B2 (en) 2015-10-16 2020-02-04 Arizona Board Of Regent On Behalf Of The University Of Arizona Compositions and methods for treating central nervous system (CNS) disorders and mood disorders
AU2017281940C1 (en) 2016-06-24 2024-11-07 University Of Iowa Research Foundation Compositions and methods of treating melanoma
US11591367B2 (en) 2016-10-04 2023-02-28 Dsm Ip Assets B.V. Melanocortin-1-receptor agonists
CA3050630A1 (en) * 2017-02-01 2018-08-09 Clinuvel Pharmaceuticals Ltd Alpha-msh analogues used in the treatment of xeroderma pigmentosum
US12364715B2 (en) 2018-02-23 2025-07-22 Enzyvant Therapeutics Gmbh Methods of determining the suitability of cultured thymus tissue for implantation into humans and associated methods of use
CA3089593A1 (en) 2018-02-23 2019-08-29 Mary Louise MARKERT Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants
US11819520B2 (en) * 2018-02-23 2023-11-21 Duke University Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants
US11529335B2 (en) 2020-07-31 2022-12-20 University Of Iowa Research Foundation Compositions and methods for treating cancer
WO2023091689A1 (en) 2021-11-19 2023-05-25 University Of Iowa Research Foundation Combined use of mcr1-directed radiotherapy and immune checkpoint inhibition in the treatment of melanoma
WO2024040167A2 (en) * 2022-08-18 2024-02-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Selective mc4r ligand for treating obesity and cognitive loss
WO2025123051A1 (en) * 2023-12-07 2025-06-12 Endevica Bio, Inc. Non-naturally occurring melanocortin analogs and uses thereof for modulating weight gain
WO2025245258A1 (en) * 2024-05-21 2025-11-27 Endevica Bio, Inc. Non-naturally occurring melanocortin receptor agonist analogs for modulating weight gain

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4731408A (en) 1985-12-20 1988-03-15 Polaroid Corporation Processable conductive polymers
DE3851002T2 (de) 1987-05-22 1995-02-02 University Patents, Inc., Westport, Conn. Lineare und zyklische Analoge von alpha-MSH-Fragmenten mit ausserordentlicher Wirkung.
US5683981A (en) 1987-05-22 1997-11-04 Competitive Technologies, Inc. Cyclic bridged analogs of α-MSH and methods thereof
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US6100048A (en) 1992-04-10 2000-08-08 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
EP0696919B1 (en) 1993-04-05 2002-01-30 Competitive Technologies, Inc. Diagnosis and treatment of erectile dysfunction
US6054556A (en) 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US7396814B2 (en) 1995-06-07 2008-07-08 Palatin Technologies, Inc. Metallopeptide compositions for treatment of sexual dysfunction
CA2158425C (en) 1995-09-15 2003-01-28 Mac E. Hadley Diagnostic and treatment of erectile dysfunction
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
IL118003A0 (en) 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
WO1998027113A2 (en) 1996-12-17 1998-06-25 Quadrant Holdings Cambridge Limited Melanocortin derivatives for specific binding of melanocortin receptor 3, 4 or 5
US5925618A (en) * 1997-03-06 1999-07-20 American Cyanamid Company Peptides useful as somatostatin antagonists
WO1999021571A1 (en) 1997-10-27 1999-05-06 Trega Biosciences, Inc. Melanocortin receptor ligands and methods of using same
US20020099003A1 (en) 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
GB9808229D0 (en) 1998-04-17 1998-06-17 Quadrant Holdings Cambridge Melanocortin receptor ligands
US6534503B1 (en) 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
US6284735B1 (en) 1998-04-28 2001-09-04 Lion Bioscience Ag HP-3228 and related peptides to treat sexual dysfunction
US6265162B1 (en) * 1998-05-05 2001-07-24 Taisei Corporation Method of identifying, detecting and monitoring microorganisms by an aromatic ring hydroxylase dioxygenase gene
SE9801571D0 (sv) 1998-05-05 1998-05-05 Wapharm Ab Melanokortin-1-receptorselektiva föreningar
SE9804614A0 (en) 1998-07-06 2000-01-07 A+ Science Invest Ab New peptides and use thereof
GB9816234D0 (en) 1998-07-24 1998-09-23 William Harvey Research Limite Compounds for use in the treatment of inflammation
ES2337321T3 (es) * 1998-10-16 2010-04-22 Otsuka Pharmaceutical Co., Ltd. Peptidos especificos neovasculares.
GB9827500D0 (en) 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
JP2002533111A (ja) 1998-12-23 2002-10-08 メルク エンド カムパニー インコーポレーテッド ヒトメラノコルチン１受容体タンパク質のスプライス変化体をコードするｄｎａ分子
US6887846B2 (en) 1999-03-24 2005-05-03 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
PT1165613E (pt) 1999-03-29 2008-07-29 Procter & Gamble Ligantes do receptor de melanocortina
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6699873B1 (en) 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US7049398B1 (en) 1999-08-12 2006-05-23 Palatin Technologies, Inc. Melanocortin metallopeptide constructs, combinatorial libraries and applications
WO2001030808A1 (en) 1999-10-27 2001-05-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor-ligand binding
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
CA2396307A1 (en) 2000-01-18 2001-07-26 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
US6600015B2 (en) 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
EP1272509A2 (en) * 2000-04-05 2003-01-08 V.I. Technologies, Inc. Prion-binding peptidic ligands and methods of using same
AU2001261363A1 (en) 2000-05-09 2001-11-20 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
GB0012370D0 (en) 2000-05-22 2000-07-12 Quadrant Holdings Cambridge Peptoids
HUP0303078A3 (en) 2000-08-30 2012-02-28 Hoffmann La Roche Cyclic peptidies process for their preparation pharmaceutical compositions containing them and their use
PL362003A1 (en) 2000-09-27 2004-10-18 The Procter & Gamble Company Melanocortin receptor ligands
US20030113263A1 (en) 2001-02-13 2003-06-19 Oregon Health And Sciences University, A Non-Profit Organization Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia
ITMI20011057A1 (it) 2001-05-22 2002-11-22 Bracco Imaging Spa Preparazione ed uso di peptidi ciclici e ramificati e loro deriati marcati come agenti terapeutici agonisti o antagonisti della colecistochi
US7342089B2 (en) 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
US7345144B2 (en) 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
CA2453515A1 (en) * 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US6960646B2 (en) 2001-07-12 2005-11-01 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptors agonists
US7328344B2 (en) 2001-09-28 2008-02-05 Imagitas, Inc. Authority-neutral certification for multiple-authority PKI environments
FR2835528B1 (fr) 2002-02-01 2004-03-12 Inst Europ Biolog Cellulaire Nouveaux derives peptidiques, leur preparation et leur application therapeutique et cosmetique
US20030186249A1 (en) 2002-04-01 2003-10-02 Zairen Sun Human TARPP genes and polypeptides
US7034004B2 (en) 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
US7618788B2 (en) * 2002-05-10 2009-11-17 Millipore Corporation Proteome epitope tags and methods of use thereof in protein modification analysis
JP2006511452A (ja) * 2002-07-03 2006-04-06 バイオ サイエンス インターナショナル インコーポレイテッド 芳香族ｄ−アミノ酸を含むペプチドおよびその利用方法
WO2004005324A2 (en) 2002-07-09 2004-01-15 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
AU2003290886A1 (en) 2002-11-14 2004-06-15 Zengen, Inc. Modified alpha-msh peptides and derivatives thereof
US7135548B2 (en) 2002-11-14 2006-11-14 Zengen, Inc. Modified α-MSH peptides and derivatives thereof
MXPA05011830A (es) 2003-05-09 2006-01-26 Novo Nordisk As Peptidos para uso en el tratamiento de la obesidad.
JP2007524584A (ja) 2003-05-09 2007-08-30 ノボ　ノルディスク　アクティーゼルスカブ 肥満の治療に使用するペプチド
WO2005000338A1 (en) 2003-06-19 2005-01-06 Eli Lilly And Company Uses of melanocortin-3 receptor (mc3r) agonist peptides
KR20060014444A (ko) 2003-06-19 2006-02-15 일라이 릴리 앤드 캄파니 멜라노코르틴 수용체 4 (ｍｃ4) 작용제 및 그의 용도
US7084111B2 (en) * 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
US20050026948A1 (en) 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
ATE361294T1 (de) 2003-08-20 2007-05-15 Lilly Co Eli Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagonartigen peptid (glp)-1-verbindung oder eines melanocortin-4- rezeptor-(mc4-)agonistschen peptids
WO2005030797A2 (en) 2003-09-30 2005-04-07 Novo Nordisk A/S Melanocortin receptor agonists
KR100661118B1 (ko) 2003-11-12 2006-12-26 주식회사 엘지생명과학 멜라노코틴 수용체의 항진제
WO2005048967A1 (en) 2003-11-24 2005-06-02 Clinuvel Pharmaceuticals Limited A method of inducing melanogenesis in humans with mc1r variant alleles
WO2005060985A1 (en) 2003-12-10 2005-07-07 Merck & Co., Inc. Inhibition of voluntary ethanol consumption with selective melanocortin 4-receptor agonists
US20070123453A1 (en) 2004-03-29 2007-05-31 Heiman Mark L Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion
CN1563076A (zh) 2004-04-02 2005-01-12 西南生物工程产业化中试基地有限公司 一种用于治疗性功能障碍的α－MSH类似物及制备方法
US7442693B2 (en) 2004-05-28 2008-10-28 Smithkline Beecham Corporation Diazepine compounds as ligands of the melanocortin 1 and/or 4 receptors
US7553944B2 (en) * 2004-07-21 2009-06-30 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
CN101076314A (zh) 2004-08-04 2007-11-21 克里纽沃药物有限公司 在对象体内诱导黑素生成的方法
TW200626611A (en) 2004-09-20 2006-08-01 Lonza Ag Peptide cyclisation
NZ554427A (en) 2004-10-08 2010-09-30 Clinuvel Pharmaceuticals Ltd Compositions and methods for inducing melanogenesis in a subject utilising afamelanotide
HRP20110405T1 (hr) 2004-10-25 2011-06-30 Centocor Ortho Biotech Inc. Mimetička tijela koja vezuju receptore melanokortina, smjese, postupci i upotrebe
WO2006048450A2 (en) 2004-11-04 2006-05-11 Novo Nordisk A/S Peptides for use in the treating obesity
EP1809665A2 (en) 2004-11-04 2007-07-25 Novo Nordisk A/S Mc4r selective peptides and their use in the treatment of obesity
CN101052650A (zh) 2004-11-04 2007-10-10 诺和诺德公司 用于治疗肥胖的新颖的肽类
WO2006048451A1 (en) 2004-11-04 2006-05-11 Novo Nordisk A/S Peptides for use in the treatment of obesity
WO2006060873A1 (en) 2004-12-09 2006-06-15 Prince Henry's Institute Of Medical Research Method for restoring reproductive function
WO2006073771A2 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
WO2006076442A2 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives
KR101306643B1 (ko) * 2005-02-09 2013-09-12 헬릭스 바이오메딕스, 인코포레이티드 항미생물성 헥사펩티드
US20080207493A1 (en) 2005-03-17 2008-08-28 Novo Nordisk A/S Compounds for Use in the Treatment of Obesity
CA2609951A1 (en) 2005-05-31 2006-12-07 Yissum Research Development Company Of The Hebrew University Of Jerusale M Backbone cyclized melanocortin stimulating hormone (.alpha.s) analogs
AU2006269261B2 (en) 2005-07-08 2009-12-17 Ipsen Pharma S.A.S. Melanocortin receptor ligands
EP1915168A4 (en) 2005-07-08 2010-03-31 Ipsen Pharma LIGANDS OF MELANOCORTIN RECEPTORS
CN1709906A (zh) 2005-07-15 2005-12-21 中国科学技术大学 α－促黑激素的环状类似肽及其应用
KR20080031414A (ko) 2005-07-18 2008-04-08 노보 노르디스크 에이/에스 비만치료에 사용하기 위한 신규 펩티드
US8466104B2 (en) 2005-08-26 2013-06-18 Abbvie Inc. Therapeutically active alpha MSH analogues
US20080227693A1 (en) 2005-08-29 2008-09-18 Palatin Technologies, Inc. Cyclic Peptide Isolation by Spray Drying
WO2007035474A2 (en) 2005-09-15 2007-03-29 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof
TW200745163A (en) * 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
US8114844B2 (en) 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
JP5424887B2 (ja) 2006-11-08 2014-02-26 チョンシー ユー ペプチド及び関連化合物の経皮送達システム
US20100056433A1 (en) 2007-01-18 2010-03-04 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
WO2008087190A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
US20100016237A1 (en) 2007-01-18 2010-01-21 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
WO2008087187A1 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
EP2106407A2 (en) 2007-01-18 2009-10-07 Novo Nordisk A/S Novel peptides for use in the treatment of obesity
AU2008247095B2 (en) 2007-03-16 2012-12-13 Pfizer Limited Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5- methyl-2,2- diphenylhexanamide
FR2914646A1 (fr) 2007-04-04 2008-10-10 Neorphys Soc Par Actions Simpl Analogues peptidiques des recepteurs des melanocortines
EP2167112A4 (en) 2007-06-15 2012-01-25 Ipsen Pharma Sas CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS
US20100329996A1 (en) 2007-09-12 2010-12-30 Glaxo Group Limited Novel Combination of Therapeutic Agents
CN101980717A (zh) 2007-11-05 2011-02-23 益普生制药股份有限公司 黑皮质素治疗胰岛素敏感的应用
EA018630B1 (ru) 2008-06-09 2013-09-30 Палатин Текнолоджиз, Инк. Специфичные к меланокортиновым рецепторам пептиды для лечения сексуальной дисфункции
WO2009151383A1 (en) 2008-06-09 2009-12-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for the treatment of obesity and other diseases associated with melanocortin receptor function
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
US20110189183A1 (en) * 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
EA021897B1 (ru) 2009-11-23 2015-09-30 Палатин Текнолоджиз, Инк. Циклические пептиды, специфичные к рецептору меланокортина-1

Similar Documents

Publication Publication Date Title
JP2013511554A5 (enExample)
JP2013511553A5 (enExample)
JP2013533864A5 (enExample)
Ehrlich et al. Cyclization of all-L-pentapeptides by means of 1-hydroxy-7-azabenzotriazole-derived uronium and phosphonium reagents
JP2012529433A5 (enExample)
TWI666026B (zh) Ｗｔ１抗原胜肽結合疫苗
RU2014137107A (ru) Пептидомиметические макроциклы
CN101597326B (zh) kahalalide F 及相关化合物
KR101904808B1 (ko) 데가렐릭스 및 이의 중간 화합물의 제조 방법
RU2013103093A (ru) Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкаганов
UA103154C2 (uk) Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його
JP2011511778A5 (enExample)
RU2014148530A (ru) Производные дипептида лизин-глутаминовая кислота
WO2015061720A3 (en) Prostacyclin compounds, compositions and methods of use thereof
AU2013221433A1 (en) Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
RU2013102991A (ru) Связанные с дипептидом лекарственные средства
JP2002530430A (ja) Ｃ型肝炎ウイルスｎｓ３プロテアーゼ阻害用の医薬組成物
ES2890676T3 (es) Procedimiento para la producción de D-arginil-2,6-dimetil-L-tirosil-L-lisil-L-fenilalaninamida
JP2017534675A5 (enExample)
JP2009108078A5 (enExample)
ES2869430T3 (es) Procedimiento para preparar D-arginil-2,6-dimetil-L-tirosil-L-lisil-L-fenilalaninamida
ES2308539T3 (es) Ciclacion de peptidos.
CA2977720C (en) Use of excess carbodiimide for peptide synthesis at elevated temperatures
JP2006505555A5 (enExample)
ES2651265T3 (es) Péptidos sintéticos con un efecto analgésico de tipo no narcótico